Cost-effectiveness--can it be measured?
Bohn
R L
RL
Program for the Analysis of Clinical Strategies, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Avorn
J
J
D003362:Cost-Benefit Analysis; D005169:Factor VIII / Q000008:administration & dosage / Q000627:therapeutic use; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D007592:Joint Diseases / Q000209:etiology / Q000517:prevention & control*; D009316:National Institutes of Health (U.S.); D014481:United States
D005169:Factor VIII